Complimentary Technical Snapshots on Merit Medical Systems and Three More Medical Supplies Stocks

Stock Research Monitor: MZOR, NXTM, and SIEN

LONDON, UK / ACCESSWIRE / June 27, 2018/ If you want a free Stock Review on MMSI sign up now at www.wallstequities.com/registration. Ahead of today’s trading session, WallStEquities.com features the Medical Instruments and Supplies manufacturing industry, which primarily researches, develops, and produces nonelectronic medical, surgical, dental, and veterinary instruments and apparatus, such as syringes, anesthesia apparatus, and blood transfusion equipment.Under evaluation this morning are these four stocks: Mazor Robotics Ltd (NASDAQ: MZOR), Merit Medical Systems Inc. (NASDAQ: MMSI), Nxstage Medical Inc. (NASDAQ: NXTM), and Sientra Inc. (NASDAQ: SIEN). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Mazor Robotics

Shares in Caesarea, Israel-based Mazor Robotics Ltd rose slightly by 0.30%, ending Tuesday’s trading session at $56.00. The stock recorded a trading volume of 186,864 shares. The Company’s shares have surged 63.84% over the past year. The stock is trading 2.67% below its 50-day moving average. Moreover, shares of Mazor Robotics, which together with its subsidiaries, engages in the development, production, and marketing of medical devices for supporting surgical procedures in the fields of orthopedics and neurosurgery in the US and internationally, have a Relative Strength Index (RSI) of 42.32.

On June 01st, 2018, research firm Cantor Fitzgerald initiated a ‘Neutral’ rating on the Company’s stock. Get the full research report on MZOR for free by clicking below at:

www.wallstequities.com/registration/?symbol=MZOR

Merit Medical Systems

South Jordan, Utah headquartered Merit Medical Systems Inc.’s stock climbed 2.85%, closing the day at $52.30 with a total trading volume of 342,191 shares. The Company’s shares have advanced 20.23% in the previous three months and 39.84% over the past year. The stock is trading 4.15% and 15.83% above its 50-day and 200-day moving averages, respectively. Additionally, shares of the Company, which designs, develops, manufactures, and markets various disposable medical devices for interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy, have an RSI of 59.26.

On May 31st, 2018, Merit Medical Systems announced that Bernard Birkett has resigned as CFO to pursue other business opportunities. Raul Parra, CPA, a Company veteran of more than eight years, has been appointed as interim CFO.

On June 01st, 2018, research firm Needham reiterated its ‘Buy’ rating on the Company’s stock, with a target price of $54 per share. Access the free research report on MMSI now by signing up at:

www.wallstequities.com/registration/?symbol=MMSI

Nxstage Medical

On Tuesday, shares in Lawrence, Massachusetts headquartered Nxstage Medical Inc. recorded a trading volume of 103,853 shares. The stock ended the day 0.57% higher at $28.15. The Company’s shares have advanced 2.33% in the past month, 15.61% in the previous three months, and 19.99% over the past year. The stock is trading above its 50-day and 200-day moving averages by 4.38% and 8.47%, respectively. Furthermore, shares of Nxstage Medical, which develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure, have an RSI of 58.63. Are you already registered with Wall St. Equities? Do so now for free, and get the report on NXTM at:

www.wallstequities.com/registration/?symbol=NXTM

Sientra

Santa Barbara, California headquartered Sientra Inc.’s stock dropped 1.16%, finishing yesterday’s session at $18.82 with a total trading volume of 300,630 shares. The Company’s shares have advanced 10.64% in the last month, 107.73% in the previous three months, and 98.11% over the past year. The stock is trading above its 50-day and 200-day moving averages by 11.73% and 36.29%, respectively. Additionally, shares of Sientra, which develops and sells medical aesthetics products to plastic surgeons in the US, have an RSI of 51.56.

On June 08th, 2018, research firm Maxim Group downgraded the Company’s stock rating from ‘Buy’ to ‘Hold’. Aspiring Member, please take a moment to register below for your free research report on SIEN at:

www.wallstequities.com/registration/?symbol=SIEN

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities

ReleaseID: 503835